We are live on ! Find out more
BGM

Burkehill Global Management Portfolio holdings

AUM $2.02B
1-Year Est. Return 85.32%
This Fund
S&P 500
This Quarter Est. Return
+11.94%
1 Year Est. Return
+85.32%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.02B
AUM Growth
+$498M
Cap. Flow
+$466M
Cap. Flow %
23.08%
Top 10 Hldgs %
41.93%
Holding
218
New
58
Increased
7
Reduced
12
Closed
36

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$147M
2
DLR icon
Digital Realty Trust
DLR
+$128M
3
FANG icon
Diamondback Energy
FANG
+$114M
4
NRG icon
NRG Energy
NRG
+$70.8M
5
SNDK
Sandisk
SNDK
+$70.6M

Top Sells

Rank Stock Value
1
ITT icon
ITT
ITT
+$60.7M
2
SOFI icon
SoFi Technologies
SOFI
+$52.4M
3
NDAQ icon
Nasdaq
NDAQ
+$48.6M
4
EL icon
Estee Lauder
EL
+$47.1M
5
ROL icon
Rollins
ROL
+$43.5M

Sector Composition

Rank Sector Weight
1 Healthcare 22.71%
2 Technology 19.4%
3 Industrials 18.69%
4 Energy 10.65%
5 Real Estate 8.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYTX icon
126
Kyverna Therapeutics
KYTX
$450M
$1.73M 0.09%
200,000
– –
JOBY icon
127
Joby Aviation
JOBY
$6.82B
$1.65M 0.08%
+200,000
New +$2.25M
OFRM
128
Once Upon a Farm PBC
OFRM
$631M
$1.64M 0.08%
+100,000
New +$2.06M
ERAS icon
129
Erasca
ERAS
$6.63B
$1.62M 0.08%
+100,000
New +$1.18M
BRCB
130
Black Rock Coffee Bar Inc
BRCB
$170M
$1.61M 0.08%
125,000
– –
BNTC icon
131
Benitec Biopharma
BNTC
$394M
$1.6M 0.08%
150,000
– –
HTFL
132
Heartflow Inc
HTFL
$2.08B
$1.58M 0.08%
65,000
– –
IMRX icon
133
Immuneering
IMRX
$279M
$1.58M 0.08%
300,000
– –
PICS
134
PicS N.V.
PICS
$1.54B
$1.57M 0.08%
+150,000
New +$2.2M
MPLT
135
MapLight Therapeutics
MPLT
$1.66B
$1.52M 0.08%
75,000
– –
IMTX icon
136
Immatics
IMTX
$1.24B
$1.48M 0.07%
150,000
– –
INVX
137
Innovex International
INVX
$1.87B
$1.46M 0.07%
+60,000
New +$1.51M
TNYA icon
138
Tenaya Therapeutics
TNYA
$168M
$1.38M 0.07%
2,000,000
– –
CMPS
139
Compass Pathways
CMPS
$1.52B
$1.38M 0.07%
+250,000
New +$1.68M
MH
140
McGraw Hill
MH
$1.9B
$1.37M 0.07%
100,000
– –
CBIO
141
Crescent Biopharma
CBIO
$602M
$1.36M 0.07%
74,000
– –
LRMR icon
142
Larimar Therapeutics
LRMR
$416M
$1.35M 0.07%
+300,000
New +$1.2M
CAI
143
Caris Life Sciences
CAI
$4.39B
$1.34M 0.07%
75,000
– –
ARX
144
Accelerant Holdings
ARX
$3.11B
$1.34M 0.07%
100,000
– –
VRDN icon
145
Viridian Therapeutics
VRDN
$2.13B
$1.27M 0.06%
65,000
– –
EIKN
146
Eikon Therapeutics
EIKN
$482M
$1.22M 0.06%
+115,000
New +$1.54M
EVMN
147
Evommune Inc
EVMN
$409M
$1.15M 0.06%
50,000
– –
LIFE
148
Ethos Technologies Inc
LIFE
$1.17B
$1.12M 0.06%
+100,000
New +$1.18M
ASPI icon
149
ASP Isotopes
ASPI
$487M
$1.1M 0.05%
250,000
– –
ESPR
150
DELISTED
Esperion Therapeutics
ESPR
$1.1M 0.05%
400,000
– –
4 5
6
7 8

Similar funds

AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return
NIM
NXG Investment Management Dallas, Texas $2.02B AUM 30.38% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.03B AUM 32.21% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
GIM
Generate Investment Management Auckland, New Zealand $2.03B AUM 26.86% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Burkehill Global Management's Q1 2026 Portfolio in Review

As of Q1 2026, Burkehill Global Management held 218 positions worth $2.02B, up 33% from $1.52B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Burkehill Global Management deployed $466M of net new capital in Q1 2026, opening 58 new positions and adding to 7 existing holdings. Its largest new stake was Eli Lilly: 145,000 shares worth $133M.

By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 19% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Nebius Group N.V., an estimated $22.5M trimmed.

  • Burkehill Global Management's largest Q1 2026 buy was Eli Lilly: 145,000 shares worth $133M.
  • Burkehill Global Management added most to Medline Inc in Q1 2026, an estimated $43.4M increase.
  • Burkehill Global Management's biggest Q1 2026 reduction was Nebius Group N.V., cutting an estimated $22.5M.
  • Burkehill Global Management fully exited ITT in Q1 2026, selling an estimated $60.7M.
  • Burkehill Global Management's ten largest holdings make up 42% of its $2.02B portfolio in Q1 2026.
  • Burkehill Global Management opened 58 new positions and closed 36 in Q1 2026.
  • Burkehill Global Management's portfolio value rose 33% quarter-over-quarter to $2.02B.

Based on Burkehill Global Management's 13F filing for Q1 2026, filed 15 May 2026.